Insider Trading Alert - MOH, NDAQ And ARE Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 20, 2014, 164 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $87.78 to $643,360,199,551.68.

Highlighted Stocks Traded by Insiders:

Molina Healthcare (MOH) - FREE Research Report

Bayer Terry who is Chief Operating Officer at Molina Healthcare sold 22,815 shares at $36.95 on Feb. 20, 2014. Following this transaction, the Chief Operating Officer owned 93,276 shares meaning that the stake was reduced by 19.65% with the 22,815-share transaction.

The shares most recently traded at $36.75, down $0.20, or 0.53% since the insider transaction. Historical insider transactions for Molina Healthcare go as follows:

  • 4-Week # shares sold: 1,329
  • 12-Week # shares sold: 3,703
  • 24-Week # shares sold: 36,203

The average volume for Molina Healthcare has been 606,300 shares per day over the past 30 days. Molina Healthcare has a market cap of $1.7 billion and is part of the health care sector and health services industry. Shares are up 5.32% year-to-date as of the close of trading on Thursday.

Molina Healthcare, Inc. provides Medicaid-related solutions to meet the health care needs of low-income families and individuals, as well as to assist state agencies in their administration of the Medicaid program. The company has a P/E ratio of 11.6. Currently there are 3 analysts that rate Molina Healthcare a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MOH - FREE

TheStreet Quant Ratings rates Molina Healthcare as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Molina Healthcare Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NASDAQ OMX Group (NDAQ) - FREE Research Report

Jochumsen Hans-Ole who is Executive Vice President at NASDAQ OMX Group sold 14,700 shares at $39.09 on Feb. 20, 2014. Following this transaction, the Executive Vice President owned 62,808 shares meaning that the stake was reduced by 18.97% with the 14,700-share transaction.

The shares most recently traded at $39.54, up $0.45, or 1.14% since the insider transaction. Historical insider transactions for NASDAQ OMX Group go as follows:

  • 4-Week # shares sold: 14,181
  • 12-Week # shares sold: 14,181
  • 24-Week # shares sold: 129,292

The average volume for NASDAQ OMX Group has been 1.2 million shares per day over the past 30 days. NASDAQ OMX Group has a market cap of $6.6 billion and is part of the financial sector and financial services industry. Shares are down 0.58% year-to-date as of the close of trading on Thursday.

The NASDAQ OMX Group, Inc. delivers trading, clearing, exchange technology, regulatory, securities listing, and public company services worldwide. The stock currently has a dividend yield of 1.31%. The company has a P/E ratio of 15.2. Currently there are 6 analysts that rate NASDAQ OMX Group a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NDAQ - FREE

TheStreet Quant Ratings rates NASDAQ OMX Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and attractive valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full NASDAQ OMX Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Alexandria Real Estate Equities (ARE) - FREE Research Report

Marcus Joel S who is Chief Executive Officer at Alexandria Real Estate Equities sold 5,000 shares at $72.32 on Feb. 20, 2014. Following this transaction, the Chief Executive Officer owned 522,220 shares meaning that the stake was reduced by 0.95% with the 5,000-share transaction.

The shares most recently traded at $72.67, up $0.35, or 0.48% since the insider transaction. Historical insider transactions for Alexandria Real Estate Equities go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 19,500
  • 24-Week # shares sold: 36,500

The average volume for Alexandria Real Estate Equities has been 490,800 shares per day over the past 30 days. Alexandria Real Estate Equities has a market cap of $5.2 billion and is part of the financial sector and real estate industry. Shares are up 14.08% year-to-date as of the close of trading on Thursday.

Alexandria Real Estate Equities, Inc., a real estate investment trust (REIT), engages in the ownership, operation, management, development, acquisition, and redevelopment of properties for the life sciences industry. The stock currently has a dividend yield of 3.75%. The company has a P/E ratio of 45.6. Currently there are 4 analysts that rate Alexandria Real Estate Equities a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARE - FREE

TheStreet Quant Ratings rates Alexandria Real Estate Equities as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Alexandria Real Estate Equities Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

Molina, Zayo Insiders Are Dumping Stock Into the New Year: Stock Whisperer

Molina, Zayo Insiders Are Dumping Stock Into the New Year: Stock Whisperer

No One Is Safe From a Trump Twitter Storm (or Rant)

No One Is Safe From a Trump Twitter Storm (or Rant)

Healthcare Stocks Mixed as Initial Obamacare Enrollment Higher Than Last Year

Healthcare Stocks Mixed as Initial Obamacare Enrollment Higher Than Last Year

CVS in Talks to Purchase Aetna, Reports Say

CVS in Talks to Purchase Aetna, Reports Say

Futures Rise Sunday as Fed Chair Yellen Hints at Rate Hike

Futures Rise Sunday as Fed Chair Yellen Hints at Rate Hike